Immunome Inc. 4

Horn Kinney, Chief Business Officer of Immunome Inc. (IMNM), was granted 31,250 RSUs and options to purchase 62,500 shares of common stock at $22.01 per share as part of an equity compensation award.

On July 23, 2026, Immunome Inc. Chief Business Officer Horn Kinney received an equity compensation package consisting of 31,250 restricted stock units (each representing one share of common stock) and a stock option grant for 62,500 shares of common stock at an exercise price of $22.01 per share. The RSUs will vest in four equal annual installments on each anniversary of the grant date, while the options will vest 25% on July 23, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent 36 months, all contingent on continued service. These are award-type, non-cash, incentive grants rather than open-market purchases or sales, and they significantly increase the executive’s potential equity exposure to Immunome over a long-dated vesting schedule ending in 2036 for the option term.

Filing Facts

CIK

1472012

Ticker

IMNM

Form

4

Source Type

fda

Accession

0001831215-26-000004

Alert Tier

5